Prurigo nodularis

US Dermatologists' Lack of Success with Current Treatment Options in Vitiligo Paves the Way for Pipeline Advanced Systemic Agents to Disrupt the Market, According to Spherix Global Insights

Retrieved on: 
Friday, June 24, 2022
Cell, Dermatology, FDA, Gastroenterology, Nephrology, Patient, Vitiligo, BSA, Alopecia areata, Disease, Industry, AbbVie, Pain, Rheumatology, Perception, Hidradenitis suppurativa, Shanda, Fatigue, Standard of care, JAK, Quality of life, Physician, Skin, Light, Upadacitinib, Maintenance, PDUFA, Safety, Mental health, Recurrence, Thought, Body surface area, Prurigo nodularis, Pfizer, Pharmaceutical industry, Generic drug, Incyte

EXTON, Pa., June 24, 2022 /PRNewswire/ -- Vitiligo is a disease that causes loss of skin color in patches when cells that produce melanin die or stop functioning.1 Spherix recently surveyed 101 US dermatologists and followed up with eleven qualitative interviews (including three with industry key opinion leaders) to assess the current and future treatment paradigm of vitiligo patients.

Key Points: 
  • Dermatologists also measure severity in terms of the patient's quality of life and the location of their vitiligo.
  • There are currently no FDA-approved treatments available for vitiligo and therefore the unmet need, regardless of disease severity, remains high.
  • In terms of standard of care, adults and adolescents currently receive similar treatment for vitiligo.
  • Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

New Research on Alopecia Areata Reveals Vast Potential for Eli Lilly's Recently Approved Olumiant Across Both the US and EU5, According to Spherix Global Insights

Retrieved on: 
Wednesday, June 22, 2022
Nephrology, Eli Lilly, FDA, Alopecia areata, Rheumatology, Safety, Dermatology, Gastroenterology, Adoption, JAK, US, Vitiligo, Disease, Physician, Clinical trial, Atopic dermatitis, Hidradenitis suppurativa, Patient, AA, Geography, Prurigo nodularis, Pharmaceutical industry, Baricitinib, EU

EXTON, Pa., June 22, 2022 /PRNewswire/ -- Spherix recently surveyed 200 EU-based dermatologists across France, Germany, Italy, Spain, and the UK and followed up with ten qualitative interviews to assess the current and future treatment paradigm of alopecia areata (AA) patients. The firm also surveyed 100 US-based dermatologists in October 2021 on the same topic area, following up with ten qualitative interviews.

Key Points: 
  • The firm also surveyed 100 US-based dermatologists in October 2021 on the same topic area, following up with ten qualitative interviews.
  • Prior to the approval (and still in the EU), dermatologists relied primarily on topical corticosteroids, followed by intralesional corticosteroids.
  • Regardless of geography, adoption of Olumiant for the treatment of AA has the potential to be swift, post commercial availability.
  • Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis

Retrieved on: 
Wednesday, June 22, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Itch, Adult, Patient, Pharmacokinetics, Nemolizumab, IGA, Prurigo nodularis, Quality of life, Safety, III, Prurigo, Pharmaceutical industry, Galderma

These phase III trial results indicate that nemolizumab has the potential to be a key therapeutic solution for patients suffering from moderate to severe prurigo nodularis.

Key Points: 
  • These phase III trial results indicate that nemolizumab has the potential to be a key therapeutic solution for patients suffering from moderate to severe prurigo nodularis.
  • OLYMPIA 2, part of the largest clinical program in prurigo nodularis to date aiming to recruit 540 patients, is a pivotal phase III clinical trial, evaluating the efficacy, safety, pharmacokinetics and immunogenicity of nemolizumab compared with placebo in adult patients with prurigo nodularis after a 16-week treatment period.
  • The results of OLYMPIA 2 provide further evidence that nemolizumab effectively improves skin lesions and pruritus in patients with prurigo nodularis.
  • A second phase III trial investigating the efficacy of nemolizumab in patients with prurigo nodularis, named OLYMPIA 1, is ongoing.

Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention

Retrieved on: 
Tuesday, June 7, 2022
IPF, CA, Itch, Movement disorders, Chronic cough, Biotechnology, SVP, CEO, Partnership, DEA, Nasdaq, Therapy, FDA, Prurigo nodularis, Commercial, Cough, Fast Track, Risk, Route of administration, Nanotechnology, Drug discovery, Nalbuphine, Genomics, Idiopathic pulmonary fibrosis, Safety, Pharmaceutical industry, HAVEN

In addition, Ms. Good will be participating in partnership meetings throughout the conference alongside Farrell Simon, SVP, Head of Commercial and Strategy.

Key Points: 
  • In addition, Ms. Good will be participating in partnership meetings throughout the conference alongside Farrell Simon, SVP, Head of Commercial and Strategy.
  • The 2022 BIO International Convention will be held in person from June 13-16, 2022 in San Diego, CA.
  • The BIO International Convention attracts 15,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships.
  • The event brings together a wide spectrum of life science and application innovators, including drug discovery, biomanufacturing, genomics, nanotechnology, and cell therapy.

ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis

Retrieved on: 
Tuesday, June 7, 2022
The Company, Anesthesiology, Johns Hopkins School of Medicine, Company, Research, Doctor of Philosophy, Associate, DHODH, ASLN, LinkedIn, Disease, Nasdaq, Skin, Commission, Allergy, Prurigo nodularis, GLOBE, Patient, Publication, Review, Duke University Hospital, Projection, Atopic dermatitis, COVID-19, Psoriasis, Autoimmune disease, NASDAQ, MD, Clinical trial, Board, Department, U.S. Securities and Exchange Commission, Safety, Pharmaceutical industry, Medical device, Dermatology

Initial findings from the collaboration will be disclosed for presentation during the second half of 2022.

Key Points: 
  • Initial findings from the collaboration will be disclosed for presentation during the second half of 2022.
  • His areas of clinical expertise include atopic dermatitis, chronic pruritus, prurigo nodularis and dermatology for ethnic skin.
  • ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients.
  • These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company").

Trevi Therapeutics to Report Q1 2022 Financial Results and Provide a Corporate Update on May 12, 2022

Retrieved on: 
Thursday, May 5, 2022
Itch, Call, EDT, Nalbuphine, Nasdaq, Idiopathic pulmonary fibrosis, Company, Safety, DEA, Review, Cough, Route of administration, FDA, Prurigo nodularis, IPF, Fast Track, Chronic cough, Movement disorders, News, Risk, Therapy, Pharmaceutical industry, Conference, Webcast

NEW HAVEN, Conn., May 5, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that management will host a conference call and live audio webcast on Thursday, May 12, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the first quarter ended March 31, 2022.

Key Points: 
  • ET, to provide a corporate update and review the Company's financial results for the first quarter ended March 31, 2022.
  • To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 5008663.
  • A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
  • An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 5, 2022
Antibody, D, COVID-19, EAACI, Forward-looking statement, Merck Sharp & Dohme Federal Credit Union, Private Securities Litigation Reform Act, Immune system, Pain, Metabolic pathway, NASDAQ, GLOBE, Company, Pembrolizumab, Merck, Judgement, Safety, Annual report, Research, Itchy, Patient, Fibrosis, Rockefeller University, Diffuse large B-cell lymphoma, Survival, Clinical trial, Hives, Inflammation, B cell, Hypersensitivity, Cancer, Risk, CD40, Eosinophilic esophagitis, Therapy, Knowledge, Form 10-K, Ovarian cancer, Skin, Cold urticaria, Gilead Sciences, Merck & Co., Prurigo nodularis, R, Disease, Allergy, Intellectual property, Contingency (philosophy), NJ, Goal, G&A, Consultant, KIT, Cell, Large-cell lung carcinoma, CD27, Online gambling, Pharmaceutical industry, Vaccine

HAMPTON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • HAMPTON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
  • Celldex is currently completing enrollment in the Phase 1b multi-center, randomized, double-blind, placebo-controlled study of barzolvolimab in chronic spontaneous urticaria.
  • Data from this study (0.5, 1.5 and 3 mg/kg cohorts) have been submitted for a late breaking presentation at EAACI 2022.
  • Celldex remains on track to initiate Phase 2 studies in chronic spontaneous urticaria and chronic inducible urticaria (cold urticaria and symptomatic dermographism) in the second quarter of 2022.

Trevi Therapeutics to Present at Upcoming May Meetings

Retrieved on: 
Tuesday, May 3, 2022
Itch, Immunology, Nalbuphine, Nasdaq, Idiopathic pulmonary fibrosis, I&I, Safety, DEA, Cough, Route of administration, FDA, Prurigo nodularis, IPF, Fast Track, Chronic cough, Movement disorders, Lists of people executed in the United States, Risk, Therapy, Pharmaceutical industry, HAVEN, Inflammation

These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

Key Points: 
  • These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
  • Founded in 2011,Trevi Therapeuticsis headquartered inNew Haven, CT.
    Haduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine.
  • The - and -opioid receptors are known to be critical mediators of itch, cough and certain movement disorders.
  • Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with -opioid agonists because it antagonizes, or blocks, -opioid receptors.

Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation

Retrieved on: 
Thursday, April 7, 2022
EOS, Wheeze, Conditional sentence, Prurigo nodularis, Clinical trial, Sex, Patient, Interleukin, Skin, European Commission, Ageing, ICS, EC, Regeneron Pharmaceuticals, Eosinophilic esophagitis, The Rheumatoid Arthritis Quality of Life Questionnaire, Safety, Hope, Union, Polyp (medicine), Nitric acid, Asthma, Sinusitis, Allergic rhinitis, Maintenance, Helminthiasis, Cough, FEV1, Atopic dermatitis, Eosinophilia, Pharmaceutical industry, EU, Dupilumab

The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union.

Key Points: 
  • The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union.
  • Up to 85% of children with asthma may have type 2 inflammation and are more likely to have higher disease burden.
  • Children with severe asthma also may require the use of multiple courses of systemic corticosteroids that carry significant risks.
  • In clinical trials, Dupixent significantly reduced asthma attacks, helped children breathe better and improved their health-related quality of life.

Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference

Retrieved on: 
Monday, April 11, 2022
Chronic cough, Company, Therapy, Idiopathic pulmonary fibrosis, Nalbuphine, News, EDT, Conference, Webcast, IPF, Itch, Nasdaq, Prurigo nodularis, Pharmaceutical industry

NEW HAVEN, Conn., April 11, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced an updated time slot for their fireside chat at the 21st Annual Needham Virtual Healthcare Conference.  Jennifer Good, President and Chief Executive Officer, along with Dr. Bill Forbes, Chief Development Officer, will participate in a fireside chat on Tuesday, April 12, 2022, at 10:15 a.m. ET.

Key Points: 
  • A live webcast of the fireside chat will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
  • An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.
  • Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.